JP2009519218A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519218A5 JP2009519218A5 JP2008540093A JP2008540093A JP2009519218A5 JP 2009519218 A5 JP2009519218 A5 JP 2009519218A5 JP 2008540093 A JP2008540093 A JP 2008540093A JP 2008540093 A JP2008540093 A JP 2008540093A JP 2009519218 A5 JP2009519218 A5 JP 2009519218A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- heteroaryl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 64
- 125000000217 alkyl group Chemical group 0.000 claims 42
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 37
- 125000001072 heteroaryl group Chemical group 0.000 claims 35
- 125000004404 heteroalkyl group Chemical group 0.000 claims 33
- 125000003118 aryl group Chemical group 0.000 claims 32
- 125000000753 cycloalkyl group Chemical group 0.000 claims 28
- 229910052739 hydrogen Inorganic materials 0.000 claims 26
- 239000001257 hydrogen Substances 0.000 claims 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims 1
- 125000006735 (C1-C20) heteroalkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004474 heteroalkylene group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- -1 phenyl compound Chemical class 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- KCROKNODFCWCEM-UHFFFAOYSA-N CC(C)C(CO)NC(c1ccc(-c2ccnc(Nc3cc(C(C)O)ccc3)n2)[s]1)=O Chemical compound CC(C)C(CO)NC(c1ccc(-c2ccnc(Nc3cc(C(C)O)ccc3)n2)[s]1)=O KCROKNODFCWCEM-UHFFFAOYSA-N 0.000 description 1
- BKZZNZPCJFJXAK-UHFFFAOYSA-N CC(C)N(C)C(c1ccc(-c2ccnc(Nc3cc(C(C)O)ccc3)n2)[s]1)=O Chemical compound CC(C)N(C)C(c1ccc(-c2ccnc(Nc3cc(C(C)O)ccc3)n2)[s]1)=O BKZZNZPCJFJXAK-UHFFFAOYSA-N 0.000 description 1
- IICMHPJXSLGYOG-UHFFFAOYSA-N CC(c1cc(Nc2nc(-c3ccc(CNC(c4ccccc4)=O)[s]3)ccn2)ccc1)O Chemical compound CC(c1cc(Nc2nc(-c3ccc(CNC(c4ccccc4)=O)[s]3)ccn2)ccc1)O IICMHPJXSLGYOG-UHFFFAOYSA-N 0.000 description 1
- ZXNCTJHFAIKWIU-UHFFFAOYSA-N CC(c1cccc(Nc2nc(-c3ccc(C(C(Cc4cccc(Cl)c4)=N)=O)[s]3)ccn2)c1)O Chemical compound CC(c1cccc(Nc2nc(-c3ccc(C(C(Cc4cccc(Cl)c4)=N)=O)[s]3)ccn2)c1)O ZXNCTJHFAIKWIU-UHFFFAOYSA-N 0.000 description 1
- UWBRFPBAGAPRSU-UHFFFAOYSA-N CC(c1cccc(Nc2nc(-c3ccc(C(N(C)Cc4ccccc4)=O)[s]3)ccn2)c1)O Chemical compound CC(c1cccc(Nc2nc(-c3ccc(C(N(C)Cc4ccccc4)=O)[s]3)ccn2)c1)O UWBRFPBAGAPRSU-UHFFFAOYSA-N 0.000 description 1
- ALBCWDTZFGFHRV-UHFFFAOYSA-N CC(c1cccc(Nc2nc(-c3ccc(C(N(CCC#N)C4CC4)=O)[s]3)ccn2)c1)O Chemical compound CC(c1cccc(Nc2nc(-c3ccc(C(N(CCC#N)C4CC4)=O)[s]3)ccn2)c1)O ALBCWDTZFGFHRV-UHFFFAOYSA-N 0.000 description 1
- VOYQLZMCJHGSHA-UHFFFAOYSA-N CC(c1cccc(Nc2nc(-c3ccc(C(NCCc4ccccc4)=O)[s]3)ccn2)c1)O Chemical compound CC(c1cccc(Nc2nc(-c3ccc(C(NCCc4ccccc4)=O)[s]3)ccn2)c1)O VOYQLZMCJHGSHA-UHFFFAOYSA-N 0.000 description 1
- PMFMCTRYGVCTJI-UHFFFAOYSA-N CC(c1cccc(Nc2nc(-c3ccc(C(NCc(cc4)ccc4OC)=O)[s]3)ccn2)c1)O Chemical compound CC(c1cccc(Nc2nc(-c3ccc(C(NCc(cc4)ccc4OC)=O)[s]3)ccn2)c1)O PMFMCTRYGVCTJI-UHFFFAOYSA-N 0.000 description 1
- DPVUAYHFLOAFRA-UHFFFAOYSA-N CC(c1cccc(Nc2nc(-c3ccc(C(NCc4cccc(OC)c4)=O)[s]3)ccn2)c1)O Chemical compound CC(c1cccc(Nc2nc(-c3ccc(C(NCc4cccc(OC)c4)=O)[s]3)ccn2)c1)O DPVUAYHFLOAFRA-UHFFFAOYSA-N 0.000 description 1
- XCRGAOZQJYVEEQ-UHFFFAOYSA-N CC(c1cccc(Nc2nc(-c3ccc(C(NCc4ccccc4)=O)[s]3)ccn2)c1)O Chemical compound CC(c1cccc(Nc2nc(-c3ccc(C(NCc4ccccc4)=O)[s]3)ccn2)c1)O XCRGAOZQJYVEEQ-UHFFFAOYSA-N 0.000 description 1
- IOAJFSHRVHGWOK-UHFFFAOYSA-N CCN(CC)C(c1ccc(-c2ccnc(Nc3cc(C(C)O)ccc3)n2)[s]1)=O Chemical compound CCN(CC)C(c1ccc(-c2ccnc(Nc3cc(C(C)O)ccc3)n2)[s]1)=O IOAJFSHRVHGWOK-UHFFFAOYSA-N 0.000 description 1
- XAWZOPBSCYFKQY-UHFFFAOYSA-N CCN(CCC#N)C(c1ccc(-c2ccnc(Nc3cc(C(C)O)ccc3)n2)[s]1)=O Chemical compound CCN(CCC#N)C(c1ccc(-c2ccnc(Nc3cc(C(C)O)ccc3)n2)[s]1)=O XAWZOPBSCYFKQY-UHFFFAOYSA-N 0.000 description 1
- PQSHMCYZQQUDBD-UHFFFAOYSA-N CN(C)CCN(CC1)CCN1C(c1cccc(Nc2nc(-c([s]3)ccc3Br)ccn2)c1)=O Chemical compound CN(C)CCN(CC1)CCN1C(c1cccc(Nc2nc(-c([s]3)ccc3Br)ccn2)c1)=O PQSHMCYZQQUDBD-UHFFFAOYSA-N 0.000 description 1
- NEOJLLSTUVXWLJ-UHFFFAOYSA-N CN(C)CCNC(c(cc1)ccc1Nc1nc(-c([s]2)ccc2Br)ccn1)=O Chemical compound CN(C)CCNC(c(cc1)ccc1Nc1nc(-c([s]2)ccc2Br)ccn1)=O NEOJLLSTUVXWLJ-UHFFFAOYSA-N 0.000 description 1
- CELYBXVMDXCQDF-UHFFFAOYSA-N CN(C1CCN(C)CC1)C(c(cc1)ccc1Nc1nc(-c([s]2)ccc2Br)ccn1)=O Chemical compound CN(C1CCN(C)CC1)C(c(cc1)ccc1Nc1nc(-c([s]2)ccc2Br)ccn1)=O CELYBXVMDXCQDF-UHFFFAOYSA-N 0.000 description 1
- DIRFBMXRRUCJQV-UHFFFAOYSA-N Cc1cc(NC2=NC=CC(c3cc(Br)c[s]3)=[I]2)ccc1 Chemical compound Cc1cc(NC2=NC=CC(c3cc(Br)c[s]3)=[I]2)ccc1 DIRFBMXRRUCJQV-UHFFFAOYSA-N 0.000 description 1
- YXHWUNMVTJYHHH-UHFFFAOYSA-N Cc1cccc(Nc2nc(-c3ccc(NCc(cc4)ccc4Cl)[s]3)ccn2)c1 Chemical compound Cc1cccc(Nc2nc(-c3ccc(NCc(cc4)ccc4Cl)[s]3)ccn2)c1 YXHWUNMVTJYHHH-UHFFFAOYSA-N 0.000 description 1
- FNQQKSOOTSPRJP-UHFFFAOYSA-N Cc1cccc(Nc2nc(-c3ccc(NCc4ccc[o]4)[s]3)ccn2)c1 Chemical compound Cc1cccc(Nc2nc(-c3ccc(NCc4ccc[o]4)[s]3)ccn2)c1 FNQQKSOOTSPRJP-UHFFFAOYSA-N 0.000 description 1
- IBVSMRYEKZHCJP-UHFFFAOYSA-N Cc1cccc(Nc2nc(-c3ccc(NCc4ccccc4)[s]3)ccn2)c1 Chemical compound Cc1cccc(Nc2nc(-c3ccc(NCc4ccccc4)[s]3)ccn2)c1 IBVSMRYEKZHCJP-UHFFFAOYSA-N 0.000 description 1
- HPJHBQIXAZLZMX-UHFFFAOYSA-N Cc1cccc(Nc2nc(-c3ccc(NCc4ncccc4)[s]3)ccn2)c1 Chemical compound Cc1cccc(Nc2nc(-c3ccc(NCc4ncccc4)[s]3)ccn2)c1 HPJHBQIXAZLZMX-UHFFFAOYSA-N 0.000 description 1
- YMPUCUJQWDCRBQ-UHFFFAOYSA-N O=C(c(cc1)ccc1Nc1nc(-c([s]2)ccc2Br)ccn1)N(CC1)CCC1N1CCCC1 Chemical compound O=C(c(cc1)ccc1Nc1nc(-c([s]2)ccc2Br)ccn1)N(CC1)CCC1N1CCCC1 YMPUCUJQWDCRBQ-UHFFFAOYSA-N 0.000 description 1
- XIZLDFYIJSOPRM-UHFFFAOYSA-N OC1CCN(Cc2cc(Nc3nc(-c4ccc(CNc5ccccc5)[s]4)ccn3)ccc2)CC1 Chemical compound OC1CCN(Cc2cc(Nc3nc(-c4ccc(CNc5ccccc5)[s]4)ccn3)ccc2)CC1 XIZLDFYIJSOPRM-UHFFFAOYSA-N 0.000 description 1
- GQBWSZFJPHLQFQ-UHFFFAOYSA-N OCCN(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c([s]2)ccc2Br)ccn1)=O Chemical compound OCCN(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c([s]2)ccc2Br)ccn1)=O GQBWSZFJPHLQFQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73358505P | 2005-11-03 | 2005-11-03 | |
| PCT/US2006/043047 WO2007053776A1 (en) | 2005-11-03 | 2006-11-02 | Pyrimidinyl-thiophene kinase modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009519218A JP2009519218A (ja) | 2009-05-14 |
| JP2009519218A5 true JP2009519218A5 (https=) | 2009-12-17 |
Family
ID=37726766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008540093A Withdrawn JP2009519218A (ja) | 2005-11-03 | 2006-11-02 | ピリミジニル−チオフェンキナーゼモジュレータ |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7803806B2 (https=) |
| EP (1) | EP1948647A1 (https=) |
| JP (1) | JP2009519218A (https=) |
| CA (1) | CA2628474A1 (https=) |
| WO (1) | WO2007053776A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1907385A4 (en) * | 2005-07-26 | 2009-05-06 | Smithkline Beecham Corp | LINKS |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| CN103626742B (zh) | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| BRPI0709949A2 (pt) * | 2006-04-12 | 2011-08-30 | Wyeth Corp | composto de fórmula iii; método de inibir atividade quinase em uma célula; método de inibir atividade quinase em um mamìfero; composição farmacêutica; método de tratar uma condição dependente de quinase; método de tratar uma doença associada com ativação de nf-kb; método de tratar proliferação de célula tumoral, crescimento de célula tumoral, ou tumorigênese; método de reduzir inflamação; método de tratar uma condição inflamatória ou autoimune; método de tratar uma condição cardiovascular, metabólica ou isquêmica; método de tratar uma doença infecciosa; método de tratar uma condição pré ou pós menopausa; e método de tratar osteoporose |
| CA2697077C (en) * | 2007-08-22 | 2012-10-16 | Irm Llc | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors |
| WO2009046416A1 (en) * | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| WO2009073575A2 (en) * | 2007-11-30 | 2009-06-11 | Oregon Health & Science University | Methods for treating induced cellular proliferative disorders |
| GB0724251D0 (en) | 2007-12-12 | 2008-02-06 | Univ Edinburgh | Therapeutic compounds and their use |
| US8309566B2 (en) | 2008-02-15 | 2012-11-13 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases |
| GB0804685D0 (en) * | 2008-03-13 | 2008-04-16 | Univ Edinburgh | Therapeutic compounds and their use |
| US20100130476A1 (en) * | 2008-11-12 | 2010-05-27 | The Scripps Research Institute | Compounds that induce pancreatic beta-cell expansion |
| EP2443113A1 (en) | 2009-06-15 | 2012-04-25 | The University Of Edinburgh | Amido-isothiazole compounds and their use as inhibitors of 11beta-hsd1 for the treatment of metabolic syndrome and related disorders |
| EP2477983B1 (en) | 2009-09-16 | 2015-04-15 | The University Of Edinburgh | (4-phenyl-piperidin-1-yl)-[5-1h-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use |
| WO2011135276A1 (en) | 2010-04-29 | 2011-11-03 | The University Of Edinburgh | 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1h - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -hsd1 |
| NZ604708A (en) | 2010-05-20 | 2015-05-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
| CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| AU2011328237A1 (en) | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
| TWI704151B (zh) * | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
| WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| EP3849986B1 (en) | 2018-09-10 | 2022-06-08 | Array Biopharma, Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| CN111961034A (zh) * | 2019-05-20 | 2020-11-20 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
| CN110734428A (zh) * | 2019-10-24 | 2020-01-31 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| CN110627775B (zh) * | 2019-10-24 | 2026-01-30 | 特科罗生物科技(成都)有限公司 | 一种小分子化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604091A (en) * | 1984-03-01 | 1997-02-18 | Microgenics Corporation | Methods for protein binding enzyme complementation |
| DE3751742T3 (de) * | 1986-01-13 | 2002-11-21 | American Cyanamid Co., Wayne | 4,5,6-Substituierte 2-Pyrimidinamine |
| US5064963A (en) | 1990-04-25 | 1991-11-12 | American Cyanamid Company | Process for the synthesis of n-(3-(1h-imidazol-1-yl)phenyl-4-(substituted)-2-pyrimidinamines |
| US5162328A (en) * | 1991-12-31 | 1992-11-10 | American Cyanamid Company | N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-2-pyrimidinamine and pharmacologically acceptable salts |
| US5182328A (en) * | 1992-03-04 | 1993-01-26 | Air Products And Chemicals, Inc. | RF curable Type I wood adhesive composition comprising vinyl acetate/NMA copolymer emulsions containing tetramethylol glycoluril |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
| US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| MXPA03009378A (es) * | 2001-04-13 | 2004-01-29 | Vertex Pharma | Inhibidores de cinasas c-jun n-terminales (jnk) y otras proteinas cinasas. |
| US20030229453A1 (en) | 2002-04-09 | 2003-12-11 | Antonysamy Stephen Suresh | Crystals and structures of PAK4KD kinase PAK4KD |
| MXPA06010520A (es) | 2004-03-30 | 2007-03-26 | Chiron Corp | Derivados de tiofeno sustituidos como agentes anticancerosos. |
| MX2007004488A (es) * | 2004-10-13 | 2007-09-11 | Wyeth Corp | Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos. |
| EP1907385A4 (en) | 2005-07-26 | 2009-05-06 | Smithkline Beecham Corp | LINKS |
-
2006
- 2006-11-02 US US11/556,033 patent/US7803806B2/en not_active Expired - Fee Related
- 2006-11-02 CA CA002628474A patent/CA2628474A1/en not_active Abandoned
- 2006-11-02 EP EP06836919A patent/EP1948647A1/en not_active Withdrawn
- 2006-11-02 WO PCT/US2006/043047 patent/WO2007053776A1/en not_active Ceased
- 2006-11-02 JP JP2008540093A patent/JP2009519218A/ja not_active Withdrawn
-
2010
- 2010-08-06 US US12/851,671 patent/US7977481B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009519218A5 (https=) | ||
| JP2007501859A5 (https=) | ||
| JP2005511536A5 (https=) | ||
| JP2007534702A5 (https=) | ||
| JP2009529540A5 (https=) | ||
| JP2015523439A5 (ja) | 量子ドット結合用リガンド及び組成物 | |
| JP2005503385A5 (https=) | ||
| JP2020518669A5 (https=) | ||
| JP2011137006A5 (https=) | ||
| JP2011522789A5 (https=) | ||
| JP2005508905A5 (https=) | ||
| JP2005504811A5 (ja) | 置換ペンタセン化合物、半導体デバイス及び物品 | |
| JP2005516040A5 (https=) | ||
| AR050436A1 (es) | Inhibidores de azaindol de mtp y apob | |
| JP2005511545A5 (https=) | ||
| JP2008530102A5 (https=) | ||
| JP2005525294A5 (https=) | ||
| JP2013210632A5 (https=) | ||
| JP2018519357A5 (https=) | ||
| JPH1180569A5 (https=) | ||
| AR046202A1 (es) | Compuestos nucleosidicos para el tratamiento de infecciones virales | |
| JP2007523941A5 (https=) | ||
| JP2006517201A5 (https=) | ||
| JP2000267287A5 (https=) | ||
| JP2005054150A5 (https=) |